Sciomics GmbH

[On Demand]
Protein profiling plays an essential part in today’s biomedical research, striving to improve patients’ quality of life by using molecular signatures for diagnosis and treatment guidance.

At Sciomics, we believe that our explorative proteomic and post-translational modification profiling platform enables true progress in precision medicine. Therefore, our internal development pipeline of innovative biomarker signatures for precision medicine is based on this powerful platform. In the focus of our development activities are a biomarker signature for prediction and early diagnosis of peri operative acute kidney injury as well as markers to predict a severe COVID-19 disease next to precision oncology.
In addition, we offer services based on our scioDiscover profiling platform and R&D collaborations for the discovery and validation of novel biomarkers, for drug target screening, and for the analysis of pathway activity as well as mode-of-action analyses.
Founder & CEO